Physician profile
Samuel K Turner
NPI 1356340368
$3,484.56
in general payments reported to CMS, 2019-2025
32 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $218 · 2021: $543 · 2022: $711 · 2023: $596 · 2024: $423 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $425.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $336.45 | 2019-2023 | Livalo, Seglentis |
| Abbott Laboratories | $292.13 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $275.70 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $241.22 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $209.39 | 2021-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $175.06 | 2019-2025 | |
| Dexcom, INC. | $156.98 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $156.14 | 2019-2024 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.92 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.74 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $131.28 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $116.75 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.13 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $103.81 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98.91 | 2019-2023 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $74.67 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $48.86 | 2022 | |
| Eisai INC. | $30.63 | 2021 | |
| Mylan Specialty L.P. | $25.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.78 | 2022 | |
| Amarin Pharma, INC. | $18.73 | 2020 | |
| Viatris Specialty LLC | $18.36 | 2025 | Yupelri |
| Genentech USA, INC. | $18.28 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.35 | 2021 | |
| Tandem Diabetes Care, INC. | $17.27 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Otsuka America Pharmaceutical, INC. | $14.80 | 2025 | Rexulti |
| Medtronic, INC. | $14.45 | 2021 | |
| Insulet Corporation | $13.15 | 2023 | Omnipod |
| Radius Health, INC. | $12.65 | 2019 | |
| Medtronic Minimed, INC. | $12.44 | 2020 | |
| Glaxosmithkline, LLC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.